Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Zhang(Peking Union Medical College Hospital), Xiaoqing Liu(Academy of Military Medical Sciences), Caicun Zhou(Shanghai Pulmonary Hospital), Li Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Shucai Zhang(Capital Medical University), Dong Wang(Daping Hospital), Qiang Li(Second Military Medical University), Shukui Qin(81th Hospital of PLA), Chunhong Hu(Central South University), Yiping Zhang(Zhejiang Cancer Hospital), Jianhua Chen(Hunan Cancer Hospital), Ying Cheng(Jilin Province Tumor Hospital), Jifeng Feng(Jiangsu Cancer Hospital), Helong Zhang(Air Force Medical University), Yong Song(Nanjing General Hospital of Nanjing Military Command), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Nong Xu(First Affiliated Hospital Zhejiang University), Jianying Zhou(First Affiliated Hospital Zhejiang University), Rongcheng Luo(Southern Medical University), Chunxue Bai(Fudan University), Jin Ye-ning(Shanghai Jiao Tong University), Wenchao Liu(Air Force Medical University), Zhaohui Wei, Fenlai Tan(Zhejiang Yongning Pharma (China)), Yinxiang Wang(Zhejiang Yongning Pharma (China)), Lieming Ding(Zhejiang Yongning Pharma (China)), Hong Dai(Beijing Chao-Yang Hospital), Shunchang Jiao(People's Liberation Army No. 150 Hospital), Jie Wang(Peking University), Li Liang(Peking University), Weimin Zhang(General Hospital of Guangzhou Military Command), Yan Sun(Chinese Academy of Medical Sciences & Peking Union Medical College)
The Lancet Oncology
August 13, 2013
Cited by 421

Abstract


Related Papers

No related papers found

Powered by citation graph analysis